Monitor System for the Safety of Dabigatran Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1496 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-03-22

Study Completion Date

2018-04-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether dabigatran is associated with higher risk of bleeding in Asia area especially in China clinical practice and whether it need to set up a monitor system.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients

NCT02646267

Atrial Fibrillation

UNKNOWN PHASE4

Dabigatran Versus Warfarin With NVAF Who Undergo PCI

NCT03536611

Atrial Fibrillation Coronary Artery Disease

UNKNOWN PHASE4

Comparative Effectiveness and Safety Between Warfarin and Dabigatran

NCT03254134

Atrial Fibrillation

COMPLETED

D-dimer In Patients With atRial Fibrillation rEceiving antiCoagulation Therapy

NCT03280641

Atrial Fibrillation Strokes Thrombotic

COMPLETED

The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage

NCT02043808

Atrial Fibrillation

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Dabigatran is administered in a fixed does without laboratory monitoring and is being compared with warfarin (international normalized ratio, but only hundreds of evidence from Asia events in several multicenter, prospective, randomized trails. It remains unclear that whether Dabigatran is safety in China clinical practice and no need of monitor test. We identified participants as those diagnosed as having nonvalved atrial fibrillation, and who initiated dabigatran after diagnosis.We followed up each individual from the first prescription of dabigatran until discontinued use or switch of anticoagulants, death, or other outcomes or until one year later. We categorized bleeding events as major and minor events according to anatomical position. We defined time to bleeding as days between the first dabigatran prescription and the date of the bleeding event. We analyzed the time to the first bleeding event, as well as the time to the first major hemorrhage, intracranial hemorrhage, gastrointestinal bleeding, hematuria, vaginal bleeding, hemarthrosis, hemoptysis, and epistaxis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age\>18 y at entry
2. AF documented as follows: The patients has a symptomatic episode of paroxysmal or persistent AF documented by 12-lead ECG, rhythm strip, pacemaker/implantable cardioverter-defibrillator electrogram, or Holter ECG
3. In addition to documented AF, patients must have ≥1 CHADS2-VAS scores
4. We identified participants as those diagnosed as having AF, and who initiated dabigatran after diagnosis
5. Written, informed consent

Exclusion Criteria

1. History of heart valve disorders (ie, prosthetic valve or hemodynamically relevant valve disease)
2. Severe, disabling stroke, or any stroke within the previous 14d
3. Acute coronary syndrome within 1 year in AF patients
4. Conditions associated with an increased risk of bleeding

1. Major surgery in the previous month
2. History of intracranial, intraocular, spinal, retroperitoneal or atraumatic intra-articular bleeding
3. Gastrointestinal hemorrhage or hematuria
5. Severe renal impairment (estimated creatinine clearace≤30ml/min)
6. Severe liver dysfunction
7. Alcohol abuse or drug addiction
8. Patients who have received an investigational drug at this time
9. Patients considered unreliable by the investigator or have a life expectancy less than the expected duration of the trail

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No